Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Nat Biomed Eng. 2021 Jul;5(7):678-689. doi: 10.1038/s41551-021-00752-7. Epub 2021 Jun 28.
Assays for cancer diagnosis via the analysis of biomarkers on circulating extracellular vesicles (EVs) typically have lengthy sample workups, limited throughput or insufficient sensitivity, or do not use clinically validated biomarkers. Here we report the development and performance of a 96-well assay that integrates the enrichment of EVs by antibody-coated magnetic beads and the electrochemical detection, in less than one hour of total assay time, of EV-bound proteins after enzymatic amplification. By using the assay with a combination of antibodies for clinically relevant tumour biomarkers (EGFR, EpCAM, CD24 and GPA33) of colorectal cancer (CRC), we classified plasma samples from 102 patients with CRC and 40 non-CRC controls with accuracies of more than 96%, prospectively assessed a cohort of 90 patients, for whom the burden of tumour EVs was predictive of five-year disease-free survival, and longitudinally analysed plasma from 11 patients, for whom the EV burden declined after surgery and increased on relapse. Rapid assays for the detection of combinations of tumour biomarkers in plasma EVs may aid cancer detection and patient monitoring.
通过分析循环细胞外囊泡 (EVs) 上的生物标志物进行癌症诊断的检测方法通常需要冗长的样本处理、有限的通量或灵敏度不足,或者没有使用经过临床验证的生物标志物。在这里,我们报告了一种 96 孔板检测方法的开发和性能,该方法通过抗体包被的磁性珠对 EVs 的富集,以及在不到一个小时的总检测时间内,通过酶扩增对 EV 结合蛋白进行电化学检测。我们使用该检测方法结合了针对结直肠癌 (CRC) 的临床相关肿瘤标志物 (EGFR、EpCAM、CD24 和 GPA33) 的抗体,对 102 名 CRC 患者和 40 名非 CRC 对照者的血浆样本进行了分类,其准确率超过 96%,前瞻性评估了 90 名患者的队列,其中肿瘤 EV 负担可预测五年无病生存率,对 11 名患者进行了纵向分析,这些患者在手术后 EV 负担下降,复发时增加。用于检测血浆 EVs 中肿瘤生物标志物组合的快速检测方法可能有助于癌症检测和患者监测。